Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects

Atomic Force F+E and Asylum Research, the technology leader in scanning probe/atomic force microscopy (AFM/SPM) announce the first European AFM in Biology Class to be held February 23-25, 2010 at Atomic Force Corporate office in Mannheim, Germany.

Investors and corporate licensees from Fortune 1000 companies will meet once again in Arlington, Texas for the eighth annual WBTshowcase (WBT2010), the world's largest forum offering a prescreened, pre-prepped collection of undiscovered companies and intellectual property emanating from top universities, labs and research institutions from across the country.

Luna Innovations Incorporated has acquired certain intellectual property assets of Tego Biosciences, its main competitor in developing medicines based on carbon nanomaterials.

Dr Thierry Bontoux has stepped down from his position of Deputy Director of the LCN in charge of Business. His decision will be effective from the 31st of December 2009 and he will then focus on his new venture, TBx-Consulting.

mPhase Technologies, Inc. has retained the Investor Relations Group to serve as its national investor relations agency.

Am Leibniz-Institut fuer Festkoerper- und Werkstoffforschung Dresden (IFW) wird ab 1.1.2010 eine von der Deutschen Forschungsgemeinschaft (DFG) gefoerderte Emmy Noether-Nachwuchsgruppe eingerichtet. Mit dem auf 5 Jahre angelegten Projekt sollen die Wechselwirkungen der Elektronen erforscht und simuliert werden, die bei physikalischen Phaenomenen wie Supraleitung oder Magnetismus eine wichtige Rolle spielen.

It's the ultimate goal in the treatment of cancer: tailoring a person's therapy based on his or her genetic makeup. While a lofty goal, scientists are steadily moving forward, rapidly exploiting new technologies. Researchers at Georgetown Lombardi Comprehensive Cancer Center report a significant advance in this field of research using a new chip that looks for hundreds of mutations in dozen of genes.

Half a protein is better than none, and in this case, it's way better than a whole one. Researchers have discovered that dividing a particular fluorescent protein and using it as a tag is handy for analyzing the workings of live cells, particularly in the way they employ iron-sulfur clusters.

Scientists have identified a novel antifreeze molecule in a freeze-tolerant Alaska beetle able to survive temperatures below minus 100 degrees Fahrenheit. Unlike all previously described biological antifreezes that contain protein, this new molecule, called xylomannan, has little or no protein. It is composed of a sugar and a fatty acid and may exist in new places within the cells of organisms.